Guangdong Zhongsheng Pharmaceutical Co., Ltd. 2025 Annual Report Summary
Securities Code: 002317 Securities Abbreviation: Zhongsheng Pharma Announcement Number: 2026-021
I. Important Notice
This annual report summary is derived from the full annual report. To fully understand the company's operating results, financial status, and future development plans, investors should carefully read the full annual report on the designated media of the China Securities Regulatory Commission.
All directors attended the board meeting to review this report.
Non-standard Audit Opinion Notice □ Applicable ☑ Not Applicable
Board of Directors' Review of Profit Distribution Proposal or Capital Reserve Transfer to Share Capital Proposal for the Reporting Period ☑ Applicable □ Not Applicable
Whether to transfer capital reserve to share capital □ Yes ☑ No
The profit distribution proposal reviewed and approved by the board of directors for the reporting period is: based on 849,930,477 shares, a cash dividend of RMB 2.00 per 10 shares (tax inclusive), 0 bonus shares (tax inclusive), and no transfer of capital reserve to share capital.
Board of Directors' Resolution on Preferred Share Profit Distribution Proposal for the Reporting Period □ Applicable ☑ Not Applicable
II. Company Basic Information
- Company Profile
Stock Abbreviation: Zhongsheng Pharma Stock Code: 002317 Stock Exchange: Shenzhen Stock Exchange Previous Stock Abbreviation (if any): Not Applicable
Contacts and Contact Information
| Name | Board Secretary | Securities Affairs Representative |
|---|---|---|
| Yang Wei | Chen Ziming | |
| Office Address | Information Industrial Park, Xihu Industrial Zone, Shilong Town, Dongguan City, Guangdong Province | Information Industrial Park, Xihu Industrial Zone, Shilong Town, Dongguan City, Guangdong Province |
| Fax | 0769-86188082 | 0769-86188082 |
| Phone | 0769-86188130 | 0769-86188130 |
| zqb@zspcl.com | zqb@zspcl.com |
- Introduction to Main Business and Products in the Reporting Period
The company is a high-tech enterprise, a national intellectual property demonstration enterprise, a specialized and refined small and medium-sized enterprise in Guangdong Province, and a single champion enterprise in manufacturing in Guangdong Province. The company was selected for "China Pharmaceutical Industry TOP101 2025" and "China Innovative Drug Enterprise TOP101 2025".
The company's products cover major disease areas such as cardiovascular and cerebrovascular, respiratory, ophthalmology, and digestive systems. The product structure is continuously optimized, and the profitability of the main business is stable. The company adheres to the strategic positioning goal of becoming a "pharmaceutical and health enterprise based on traditional Chinese medicine, driven by innovation, and emphasizing both quality and efficiency," gradually forming a sustainable business system with innovative drugs as the leading development force, traditional Chinese patent medicines as the business cornerstone, and chemical generic drugs as beneficial support.
The company is the original creator, standard setter, industry leader, and market dominator of the compound Danshen Tong series of preparations. The company's compound Danshen Tong series products have been awarded "Representative Products of Excellent Brands in Chinese National Medicine." The company's original unique dosage form, compound Danshen Tong capsules, won first place in Guangdong Province in the "Ranking of Technological Competitiveness of Major Traditional Chinese Medicine Products." The research and application of its core key technologies won the first prize of the Guangdong Provincial Science and Technology Award, and the related invention patent won the 19th China Patent Excellence Award. Naoshentong Capsules is the company's unique product, approved as the first Class II protected traditional Chinese medicine in 2025. Its invention patent won the 20th China Patent Silver Award, and it is the only traditional Chinese medicine patent among the gold and silver awards of the China Patent Award that year.